Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRerksuppaphol S.
dc.contributor.authorRerksuppaphol L.
dc.description.abstractBackground: Hypercholesterolemia is a major risk factor for cardiovascular disease. Not all patients respond well to traditional cholesterol lowering medications. Probiotics have been evaluated for their cholesterol-lowering effects in humans with variable results. This study was performed to evaluate the efficacy of two probiotics in lowering the serum cholesterol of hypercholesterolemic patients. Materials and Methods: A randomized double-blind controlled trial was conducted comparing placebo to Lactobacillus acidophilus plus Bifidobacterium bifidum in patients diagnosed with hypercholesterolemia. Placebo or probiotic capsules were taken three times daily for six weeks. Pre- and post-treatment total cholesterol (TC), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C) and triglyceride (TG) levels and demographic parameters of the two groups were compared. From a total of 70 participants, 64 completed the assigned treatment (31 in probiotics group and 33 in the control group).The two treatment groups were matched for age, sex, weight, height, BMI, waist and hip circumferences, and blood pressure. Results: Baseline evaluation revealed no difference between the probiotics group and control group levels of TC, HDL-C, LDL-C and TG. TC levels in the probiotics group decreased during treatment (237.2 vs. 212.7 mg/dL, p<0.05). TC and LDL-C levels in the control group increased significantly from their baseline levels during treatment. TC (212.7 vs 252.8 mg/dL, p<0.001), HDL-C (52.0 vs 59.1 mg/dL, p=0.04) and LDL-C (153.9 vs 182.1 mg/dL, p<0.01) levels in the probiotics group were significantly lower at the end of treatment than the corresponding levels in the control group. Conclusion: A combination of Lactobacillus acidophilus and Bifidobacterium bifidum decreased serum total cholesterol, LDL-cholesterol and HDL-cholesterol levels in hypercholesterolemic patients over a six week period. There was no effect on serum triglyceride or fasting blood glucose levels. © 2015, Journal of Clinical and Diagnostic Research. All Rights Reserved.
dc.subjecthigh density lipoprotein cholesterol
dc.subjectlow density lipoprotein cholesterol
dc.subjectprobiotic agent
dc.subjectBifidobacterium bifidum
dc.subjectcholesterol blood level
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectdouble blind procedure
dc.subjectLactobacillus acidophilus
dc.subjectloose feces
dc.subjectmiddle aged
dc.subjectrandomized controlled trial
dc.subjectsystolic blood pressure
dc.subjectBifidobacterium bifidum
dc.subjectLactobacillus acidophilus
dc.titleA randomized double-blind controlled trial of Lactobacillus acidophilus plus bifidobacterium bifidum versus placebo in patients with hypercholesterolemia
dc.identifier.bibliograpycitationJournal of Clinical and Diagnostic Research. Vol 9, No.3 (2015)
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.

Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.